Results 41 to 50 of about 1,814 (132)
Acta Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem +5 more
wiley +1 more source
Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.ABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Jennifer N. Clements +2 more
wiley +1 more source
Clinical &Experimental Ophthalmology, Volume 53, Issue 9, Page 1156-1167, December 2025.ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt +9 more
wiley +1 more source
Clinical Case Reports, Volume 13, Issue 11, November 2025.ABSTRACT In eyes with a scleral‐fixated IOL, intravitreal triamcinolone may migrate into the anterior chamber, resulting in early‐onset elevation of IOP, even at small volumes. Prompt slit lamp and gonioscopic evaluation is recommended for patients with prior vitrectomy or posterior capsule defects to ensure timely detection and treatment.
Yuki Takagi +2 more
wiley +1 more source
Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease
Responsive Materials, Volume 3, Issue 4, November 2025.This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang +11 more
wiley +1 more source
TNOA Journal of Ophthalmic Science and ResearchPurpose: To compare the OCT angiography (OCTA)–derived parametric changes before and after intravitreal administration of ranibizumab and brolucizumab in patients with neovascular age-related macular degeneration (ARMD) and to compare the changes between
Sanjitha Vilma Moses +3 more
doaj +1 more source
Acta Ophthalmologica, Volume 103, Issue 7, Page 741-763, November 2025.Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler +17 more
wiley +1 more source
Scientific ReportsPachychoroid neovasculopathy (PNV) is characterized by increased choroidal thickness, choroidal hyperpermeability, and fluid accumulation. Given its distinct pathophysiology, PNV requires management with anti-VEGF therapy, as its treatment response ...
Areum Jeong +3 more
doaj +1 more source
Gains in the current understanding of managing neovascular AMD with brolucizumab
Journal of Ophthalmic Inflammation and Infection, 2023 Background Unresolved retinal fluid and high injection burden are major challenges for patients with neovascular age-related macular degeneration. Brolucizumab addresses these challenges by providing robust vision gains and superior fluid resolution ...
Bahram Bodaghi +4 more
doaj +1 more source
Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration
Advanced Science, Volume 12, Issue 39, October 20, 2025.There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz +4 more
wiley +1 more source